tradingkey.logo

FDA Qualifies Total Hip Bone Mineral Density As Surrogate Endpoint For Osteoporosis Drug Development

ReutersDec 19, 2025 8:22 PM

-

  • FDA: QUALIFIES TOTAL HIP BONE MINERAL DENSITY (BMD) AS SURROGATE ENDPOINT FOR OSTEOPOROSIS DRUG DEVELOPMENT

Source text: [ID:]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI